Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
Morokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480 (In Vitro)
Morokutti-Kurz et al., Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro, PLoS ONE, doi:10.1371/journal.pone.0237480 (In Vitro)
Feb 2021   Source   PDF  
  All Studies   Meta
In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post market surveillance data show that iota-carrageenan is well-tolerated with very low reported adverse events.
9 In Vitro studies support the efficacy of iota-carrageenan [Alsaidi, Bansal, Bovard, Fröba, Meister, Morokutti-Kurz, Morokutti-Kurz (B), Song, Varese].
Morokutti-Kurz et al., 17 Feb 2021, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperIota-carragee..All
Abstract: PLOS ONE RESEARCH ARTICLE Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro Martina Morokutti-Kurz1, Maria Fröba2, Philipp Graf1, Maximilian Große2, Andreas Grassauer1, Janina Auth2, Ulrich Schubert2, Eva Prieschl-Grassauer1* 1 Marinomed Biotech AG, Korneuburg, Austria, 2 Institute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany * a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Morokutti-Kurz M, Fröba M, Graf P, Große M, Grassauer A, Auth J, et al. (2021) Iotacarrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. PLoS ONE 16(2): e0237480. pone.0237480 Editor: Stephen J. Polyak, University of Washington, UNITED STATES Received: August 4, 2020 Accepted: November 24, 2020 Abstract In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iotacarrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections. Published: February 17, 2021 Copyright: © 2021 Morokutti-Kurz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. Funding: This work was co-funded by the Austrian Science Promotion Agency (FFG) project number 880687 ( Marinomed Biotech AG ( provided support in form of salaries for all authors employed by Marinomed Biotech AG. Marinomed Biotech AG had a role in study design, data collection and analysis, decision to publish, preparation of the
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop